Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Status:
Suspended
Trial end date:
2022-05-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating
patients with biliary tract cancer that has spread to other places in the body (advanced) and
has not responded to treatment (refractory). Trifluridine/tipiracil and irinotecan may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network